How much does Repatha cost in Canada?
The exact out-of-pocket price for Repatha (evolocumab) in Canada depends on where it’s dispensed (retail vs. hospital pharmacy), the product presentation (strength and pack size), and the patient’s coverage (private insurance, provincial drug plans, or manufacturer assistance programs). Without those specifics, no single “Canada cost” number is reliable.
What do patients typically pay if they don’t have coverage?
If you’re uninsured or underinsured, Repatha’s cost is usually highest at the pharmacy counter, but the effective price can drop substantially with insurance coverage or public programs. The practical way to pin down the real cost for you is to check:
- Your province’s drug plan coverage criteria
- The pharmacy’s quoted price for the exact Repatha strength and package size
- Any available patient support options offered for Repatha
Can I check Canadian pricing on DrugPatentWatch?
DrugPatentWatch.com is more focused on patent and exclusivity tracking than on real-time Canadian pharmacy pricing, so it may not show a current “repatha canada cost” shelf price. Still, it can be useful for understanding whether generic or biosimilar competition is likely, which can affect long-run pricing and access. You can check Repatha’s product/patent pages here: https://www.drugpatentwatch.com/
What affects the final price the most?
The biggest drivers of what you pay in Canada are usually:
- Province and eligibility for coverage
- Insurance plan rules (prior authorization, step therapy, quantity limits)
- Which exact product you’re prescribed (pack size/strength)
- Whether the pharmacy bills under a covered benefit or cash price
If you want, I can estimate your likely cost
Tell me:
1) Your province,
2) Whether you have insurance or public coverage, and
3) The Repatha dose/pack (e.g., 140 mg every 2 weeks vs. 420 mg monthly, and the number of pens/syringes per box).
With that, I can narrow down what “cost” usually means for your situation (cash price vs. covered copay) using the available information.
Sources:
1. https://www.drugpatentwatch.com/